These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1026957)

  • 1. Sarcoma 180 weight, DNA, and protein increase, depending on ARA-C schedule.
    Nencini P; Grassi MC
    Pharmacol Res Commun; 1976 Jun; 8(3):259-66. PubMed ID: 1026957
    [No Abstract]   [Full Text] [Related]  

  • 2. Schedule optimization of hydroxyurea and 1-beta-D-arabinofuranosylcytosine in sarcoma 180 in vitro.
    Shackney SE; Ford SS; Occhipinti SJ; Ritch PS; Riccardi R; Erickson BW
    Cancer Res; 1982 Nov; 42(11):4339-47. PubMed ID: 7127279
    [No Abstract]   [Full Text] [Related]  

  • 3. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin.
    Ritch PS; Occhipinti SJ; Cunningham RE; Shackney SE
    Cancer Res; 1981 Oct; 41(10):3881-4. PubMed ID: 7284997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 5. [The mechanism of synergistic interaction between etoposide and cytarabine].
    Ooi K
    Yakugaku Zasshi; 2002 Jul; 122(7):471-80. PubMed ID: 12136643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif.
    Wang F; Cui C; Ren Z; Wang L; Liu H; Cui G
    J Pharm Sci; 2012 Dec; 101(12):4559-68. PubMed ID: 23023730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour action of planar, organometallic rhodium(I) complexes.
    Giraldi T; Zassinovich G; Mestroni G
    Chem Biol Interact; 1974 Dec; 9(6):389-94. PubMed ID: 4434566
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine.
    Liu B; Cui C; Duan W; Zhao M; Peng S; Wang L; Liu H; Cui G
    Eur J Med Chem; 2009 Sep; 44(9):3596-600. PubMed ID: 19321234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced incorporation of 1-beta-D-arabinofuranosylcytosine by pretreatment with etoposide.
    Ooi K; Ohkubo T; Kuwabara H; Higashigawa M; Kawasaki H; Kakitoh H; Kagawa Y; Inagaki S; Sumida K; Sakurai M
    Cancer Invest; 1993; 11(4):388-92. PubMed ID: 8324643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
    Heinemann V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1989 May; 7(5):622-8. PubMed ID: 2709090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on Crocker sarcoma under the effect of alkylating agents. II. Cytochemistry of nucleic acids and proteins in malignant cells of sarcoma 180 after treatment with the antitumour drug DL-sarcolysine.
    el-Fiky SM; Taha Y
    Acta Histochem; 1969; 34(2):246-56. PubMed ID: 4986951
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
    Rahman YE; Patel KR; Cerny EA; Maccoss M
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.
    Berdel WE; Okamoto S; Danhauser-Riedl S; Hong CI; Winton EF; West CR; Rastetter J; Vogler WR
    Exp Hematol; 1989 May; 17(4):364-7. PubMed ID: 2707318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the yeast mannan preparation in relation to the effect of chemical modification.
    Oka S; Kumano N; Kurita K
    Gan; 1972 Jun; 63(3):365-9. PubMed ID: 5072835
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cytological and immunological aspects of the antitumor action of polyhexamethylene guanidine in BALB/c mice].
    Baumanis EA; Birska IA; Zakenfeld GK; Volkova VV; Luksha UE
    Eksp Onkol; 1989; 11(3):66-9. PubMed ID: 2752947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes.
    Kobayashi T; Kataoka T; Tsukagoshi S; Sakurai Y
    Int J Cancer; 1977 Oct; 20(4):581-7. PubMed ID: 914397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deoxycytidine and lethal doses of cytarabine in advanced murine leukaemia.
    Buchman VM; Svet-Moldavsky GJ; Lichinitser MR; Mkheidze DM
    Lancet; 1977 May; 1(8020):1061. PubMed ID: 67527
    [No Abstract]   [Full Text] [Related]  

  • 18. Synergistic interaction between etoposide and 1-beta-D-arabinofuranosylcytosine.
    Ohkubo T; Hori H; Higashigawa M; Kawasaki H; Kamiya H; Sakurai M; Kagawa Y; Kakito E; Sumida K; Ooi K
    Adv Exp Med Biol; 1989; 253B():355-62. PubMed ID: 2610123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antineoplastic and biochemical effects of some 5-fluoropyrimidines.
    Sartorelli AC; Creasey WA
    Cancer Res; 1967 Nov; 27(11):2201-6. PubMed ID: 6073510
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine.
    Baguley BC; Falkenhaug EM
    Eur J Cancer (1965); 1975 Jan; 11(1):43-9. PubMed ID: 1055682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.